Ki-67 biomarker identifies high-risk subtypes of triple negative breast cancer
1. Editoriale Page 1 of 1
Ki-67 for further classification of triple negative breast cancer
Triple negative breast cancer (TNBC) demonstrates poor prognosis because of aggressive
tumor biology and lack of targeted agents.
TNBC with high Ki-67 was associated with a more aggressive clinical feature despite a higher
pCR rate. Ki-67 can be used for further classification of TNBC into two subtypes with different
prognosis. Our report suggests that TNBC with residual disease and high Ki-67 expression
should be a candidate for additional postoperative treatment such as platinum-based
chemotherapy, or clinical trials specifically testing novel therapies in order to improve the
outcome for this high-risk group of patients. In addition, TNBC with high Ki-67 should be
followed-up more frequently within 3 years to guard for any recurrence
Bibliographic Reference:
Keam B et al.: "Ki-67 can be used for further classification of triple negative breast cancer
into two subtypes with different response and prognosis", Breast Cancer Res. 2011 Mar 2;13
(2):R22. [Epub ahead of print]
Bhumsuk Keam
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
http://www.senology.org/Edit_Keam.htm 03/05/2011